Between July @ and April @ we randomly assigned @ high-risk patientsto undergo transaortic TAVI with the SAPIEN XT prosthesis ( Edwards Lifesciences ) combined with either the EMBOL-X device ( group-@ , n = @ ) or without ( group-@ , n = @ ) .